The risk of developing ILD has been associated with various types of SACT, with warnings in the labels of specific ADCs, anti-programmed cell death protein 1 (PD-1) drugs, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors (TKIs) [12, 13, 26–30]. The gene discussed is MTOR; the disease is interstitial lung disease.